View in EDS HTML Full Text PDF Full Text

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.

Saved in:
Bibliographic Details
Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.
Authors: Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Hunter HJA; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.; Medicines Evaluation Unit, Manchester, United Kingdom., Papp KA; Alliance Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Gordon KB; Dermatology, Medical College of Wisconsin, Wauwatosa, Wisconsin, United States of America., Tang MT; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Enejosa JV; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Huang KC; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Raha D; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Batugedara HM; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Skinner C; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Kobel PA; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Rademacher PM; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Ghilardi N; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Fatheree P; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Jacobsen JR; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Lu TT; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.
Source: PloS one [PLoS One] 2026 Jan 23; Vol. 21 (1), pp. e0341049. Date of Electronic Publication: 2026 Jan 23 (Print Publication: 2026).
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41575986
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Warren+RB%22">Warren RB</searchLink>; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hunter+HJA%22">Hunter HJA</searchLink>; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.; Medicines Evaluation Unit, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Papp+KA%22">Papp KA</searchLink>; Alliance Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Gordon+KB%22">Gordon KB</searchLink>; Dermatology, Medical College of Wisconsin, Wauwatosa, Wisconsin, United States of America.<br /><searchLink fieldCode="AU" term="%22Tang+MT%22">Tang MT</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Enejosa+JV%22">Enejosa JV</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Huang+KC%22">Huang KC</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Raha+D%22">Raha D</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Batugedara+HM%22">Batugedara HM</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Skinner+C%22">Skinner C</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Kobel+PA%22">Kobel PA</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Rademacher+PM%22">Rademacher PM</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Ghilardi+N%22">Ghilardi N</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Fatheree+P%22">Fatheree P</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Jacobsen+JR%22">Jacobsen JR</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Lu+TT%22">Lu TT</searchLink>; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2026 Jan 23; Vol. 21 (1), pp. e0341049. <i>Date of Electronic Publication: </i>2026 Jan 23 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41575986
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0341049
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0341049
    Titles:
      – TitleFull: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Warren RB
      – PersonEntity:
          Name:
            NameFull: Hunter HJA
      – PersonEntity:
          Name:
            NameFull: Papp KA
      – PersonEntity:
          Name:
            NameFull: Gordon KB
      – PersonEntity:
          Name:
            NameFull: Tang MT
      – PersonEntity:
          Name:
            NameFull: Enejosa JV
      – PersonEntity:
          Name:
            NameFull: Huang KC
      – PersonEntity:
          Name:
            NameFull: Raha D
      – PersonEntity:
          Name:
            NameFull: Batugedara HM
      – PersonEntity:
          Name:
            NameFull: Skinner C
      – PersonEntity:
          Name:
            NameFull: Kobel PA
      – PersonEntity:
          Name:
            NameFull: Rademacher PM
      – PersonEntity:
          Name:
            NameFull: Ghilardi N
      – PersonEntity:
          Name:
            NameFull: Fatheree P
      – PersonEntity:
          Name:
            NameFull: Jacobsen JR
      – PersonEntity:
          Name:
            NameFull: Lu TT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 01
              Text: 2026 Jan 23
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1